Skip to main content
Journal cover image

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation.

Publication ,  Journal Article
Kim, AH; Tatter, S; Rao, G; Prabhu, S; Chen, C; Fecci, P; Chiang, V; Smith, K; Williams, BJ; Mohammadi, AM; Judy, K; Sloan, A; Baumgartner, J ...
Published in: Neurosurgery
September 1, 2020

BACKGROUND: Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality-of-life (QoL) data. OBJECTIVE: To compare 12-mo outcomes from all subjects undergoing LITT for intracranial tumors/neoplasms. METHODS: Demographics, intraprocedural data, adverse events, QoL, hospitalizations, health economics, and survival data are collected; standard data management and monitoring occur. RESULTS: A total of 14 centers enrolled 223 subjects; the median follow-up was 223 d. There were 119 (53.4%) females and 104 (46.6%) males. The median age was 54.3 yr (range 3-86) and 72.6% had at least 1 baseline comorbidity. The median baseline Karnofsky Performance Score (KPS) was 90. Of the ablated tumors, 131 were primary and 92 were metastatic. Most patients with primary tumors had high-grade gliomas (80.9%). Patients with metastatic cancer had recurrence (50.6%) or radiation necrosis (40%). The median postprocedure hospital stay was 33.4 h (12.7-733.4). The 1-yr estimated survival rate was 73%, and this was not impacted by disease etiology. Patient-reported QoL as assessed by the Functional Assessment of Cancer Therapy-Brain was stabilized postprocedure. KPS declined by an average of 5.7 to 10.5 points postprocedure; however, 50.5% had stabilized/improved KPS at 6 mo. There were no significant differences in KPS or QoL between patients with metastatic vs primary tumors. CONCLUSION: Results from the ongoing LAANTERN registry demonstrate that LITT stabilizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real-world registry and comparative to published literature.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neurosurgery

DOI

EISSN

1524-4040

Publication Date

September 1, 2020

Volume

87

Issue

3

Start / End Page

E338 / E346

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Robotic Surgical Procedures
  • Registries
  • Quality of Life
  • Prospective Studies
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Laser Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kim, A. H., Tatter, S., Rao, G., Prabhu, S., Chen, C., Fecci, P., … Leuthardt, E. C. (2020). Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery, 87(3), E338–E346. https://doi.org/10.1093/neuros/nyaa071
Kim, Albert H., Steven Tatter, Ganesh Rao, Sujit Prabhu, Clark Chen, Peter Fecci, Veronica Chiang, et al. “Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation.Neurosurgery 87, no. 3 (September 1, 2020): E338–46. https://doi.org/10.1093/neuros/nyaa071.
Kim, Albert H., et al. “Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation.Neurosurgery, vol. 87, no. 3, Sept. 2020, pp. E338–46. Pubmed, doi:10.1093/neuros/nyaa071.
Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams BJ, Mohammadi AM, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt EC. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery. 2020 Sep 1;87(3):E338–E346.
Journal cover image

Published In

Neurosurgery

DOI

EISSN

1524-4040

Publication Date

September 1, 2020

Volume

87

Issue

3

Start / End Page

E338 / E346

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Robotic Surgical Procedures
  • Registries
  • Quality of Life
  • Prospective Studies
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Laser Therapy